JPWO2020041537A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020041537A5 JPWO2020041537A5 JP2021510030A JP2021510030A JPWO2020041537A5 JP WO2020041537 A5 JPWO2020041537 A5 JP WO2020041537A5 JP 2021510030 A JP2021510030 A JP 2021510030A JP 2021510030 A JP2021510030 A JP 2021510030A JP WO2020041537 A5 JPWO2020041537 A5 JP WO2020041537A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antigen
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 137
- 102000036639 antigens Human genes 0.000 claims description 137
- 108091007433 antigens Proteins 0.000 claims description 137
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 94
- 239000012634 fragment Substances 0.000 claims description 41
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 230000007815 allergy Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 241000282567 Macaca fascicularis Species 0.000 claims description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 4
- -1 anti-inflammatory Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000035268 Mast Cell Activation disease Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000008585 mastocytosis Diseases 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 206010016946 Food allergy Diseases 0.000 claims description 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims description 2
- 206010048908 Seasonal allergy Diseases 0.000 claims description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 2
- 206010052568 Urticaria chronic Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 230000002052 anaphylactic effect Effects 0.000 claims description 2
- 230000001387 anti-histamine Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 208000024376 chronic urticaria Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 201000004338 pollen allergy Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023172194A JP7541167B2 (ja) | 2018-08-23 | 2023-10-03 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721921P | 2018-08-23 | 2018-08-23 | |
| US62/721,921 | 2018-08-23 | ||
| PCT/US2019/047601 WO2020041537A1 (en) | 2018-08-23 | 2019-08-22 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172194A Division JP7541167B2 (ja) | 2018-08-23 | 2023-10-03 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533806A JP2021533806A (ja) | 2021-12-09 |
| JPWO2020041537A5 true JPWO2020041537A5 (enExample) | 2022-08-04 |
| JP7402223B2 JP7402223B2 (ja) | 2023-12-20 |
Family
ID=67876086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510030A Active JP7402223B2 (ja) | 2018-08-23 | 2019-08-22 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| JP2023172194A Active JP7541167B2 (ja) | 2018-08-23 | 2023-10-03 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172194A Active JP7541167B2 (ja) | 2018-08-23 | 2023-10-03 | 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11578127B2 (enExample) |
| EP (1) | EP3840841A1 (enExample) |
| JP (2) | JP7402223B2 (enExample) |
| KR (1) | KR20210049863A (enExample) |
| CN (1) | CN112888482B (enExample) |
| AU (1) | AU2019325565B2 (enExample) |
| BR (1) | BR112021003023A2 (enExample) |
| CA (1) | CA3109513A1 (enExample) |
| CL (2) | CL2021000437A1 (enExample) |
| CO (1) | CO2021003608A2 (enExample) |
| EA (1) | EA202190601A1 (enExample) |
| IL (1) | IL280745B1 (enExample) |
| MX (1) | MX2021002165A (enExample) |
| MY (1) | MY204368A (enExample) |
| PH (1) | PH12021550322A1 (enExample) |
| SG (1) | SG11202101608XA (enExample) |
| WO (1) | WO2020041537A1 (enExample) |
| ZA (1) | ZA202100919B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210049863A (ko) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도 |
| US20230056380A1 (en) * | 2020-01-31 | 2023-02-23 | Randy Leiman Allen | Methods and kit for detection of analytes |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| AU2005282720B2 (en) * | 2004-09-02 | 2011-08-04 | Genentech, Inc. | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| US9868786B2 (en) * | 2011-04-12 | 2018-01-16 | University Of Cincinnati | Methods for suppressing allergic reactions |
| WO2012169741A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN104293738A (zh) | 2013-09-11 | 2015-01-21 | 李莉 | 一种抗人FcεRⅠα亚基单克隆抗体及其应用 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| EP3180358B1 (en) | 2014-08-13 | 2020-04-01 | SuppreMol GmbH | Novel antibodies directed to fc gamma receptor iib and fc epsilon receptor |
| CN104800164B (zh) | 2015-04-13 | 2017-11-07 | 上海市第一人民医院 | 一种雷公藤免疫纳米粒及用途 |
| TWI784917B (zh) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗ｃｄ３雙特異性抗體及其用途 |
| BR112018070998A2 (pt) * | 2016-04-13 | 2019-02-26 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes |
| HRP20221202T1 (hr) * | 2016-09-23 | 2022-12-09 | Regeneron Pharmaceuticals, Inc. | Anti-muc16 (mucin 16) antitijela |
| KR20210049863A (ko) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도 |
-
2019
- 2019-08-22 KR KR1020217008580A patent/KR20210049863A/ko not_active Ceased
- 2019-08-22 AU AU2019325565A patent/AU2019325565B2/en active Active
- 2019-08-22 EA EA202190601A patent/EA202190601A1/ru unknown
- 2019-08-22 US US16/547,910 patent/US11578127B2/en active Active
- 2019-08-22 WO PCT/US2019/047601 patent/WO2020041537A1/en not_active Ceased
- 2019-08-22 JP JP2021510030A patent/JP7402223B2/ja active Active
- 2019-08-22 MX MX2021002165A patent/MX2021002165A/es unknown
- 2019-08-22 MY MYPI2021000853A patent/MY204368A/en unknown
- 2019-08-22 CA CA3109513A patent/CA3109513A1/en active Pending
- 2019-08-22 BR BR112021003023-9A patent/BR112021003023A2/pt unknown
- 2019-08-22 SG SG11202101608XA patent/SG11202101608XA/en unknown
- 2019-08-22 CN CN201980069380.5A patent/CN112888482B/zh active Active
- 2019-08-22 EP EP19765582.2A patent/EP3840841A1/en active Pending
-
2021
- 2021-02-09 IL IL280745A patent/IL280745B1/en unknown
- 2021-02-10 ZA ZA2021/00919A patent/ZA202100919B/en unknown
- 2021-02-15 PH PH12021550322A patent/PH12021550322A1/en unknown
- 2021-02-19 CL CL2021000437A patent/CL2021000437A1/es unknown
- 2021-03-19 CO CONC2021/0003608A patent/CO2021003608A2/es unknown
-
2023
- 2023-01-12 US US18/153,522 patent/US12441797B2/en active Active
- 2023-02-13 CL CL2023000442A patent/CL2023000442A1/es unknown
- 2023-10-03 JP JP2023172194A patent/JP7541167B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442581B2 (ja) | ヒトｉｌ－４受容体に対する高親和性ヒト抗体 | |
| JP7332627B2 (ja) | 最適化された抗ｔｌ１ａ抗体 | |
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| US12398200B2 (en) | Anti-allergen antibodies | |
| AU2019202447B2 (en) | Binding molecules specific for il-21 and uses thereof | |
| WO2021155634A1 (zh) | 抗人tslp抗体及其用途 | |
| US20120135010A1 (en) | High affinity human antibodies to human il-4 receptor | |
| CN112969719A (zh) | 双功能融合蛋白及其医药用途 | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| WO2022166072A1 (zh) | 针对人tslp的多种抗体及其用途 | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| US20240294655A1 (en) | Antigen binding molecules that bind light | |
| JP2022523929A (ja) | ヒトｌａｇ－３に結合する抗体、その製造方法および用途 | |
| JP2022516351A (ja) | 抗ｔｉｇｉｔ抗体 | |
| TW202229343A (zh) | Fgfr3抗體及使用方法 | |
| JP2019537449A (ja) | 抗ｇｉｔｒ抗原結合タンパク質およびその使用方法 | |
| CN112243443A (zh) | 抗trop-2抗体、其抗原结合片段及其医药用途 | |
| TW202212359A (zh) | 結合人il-33的抗體、其製備方法和用途 | |
| JP2022525937A (ja) | Ｂｔｎ２に対する特異性を有する抗体及びその使用 | |
| JPWO2020041537A5 (enExample) | ||
| US20250353928A1 (en) | Antibodies and antibody fragments that bind ige | |
| NZ772900B2 (en) | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof | |
| NZ772900A (en) | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof | |
| TW202413405A (zh) | 抗體、其抗原結合片段及其藥物用途 | |
| TW202604946A (zh) | 結合ｉｇｅ之抗體及抗體片段 |